cloudy
Sunday August 30th, 2015 5:57AM

New drug, study method show breast cancer promise

By The Associated Press
SAN ANTONIO (AP) -- A novel and faster way to test cancer drugs has yielded its first big result: An experimental medicine that shows promise against a hard-to-treat form of breast cancer.

The method involves studying drugs in small groups of people to quickly separate winners from duds.

Bringing a new cancer drug to market usually takes more than a decade and tests in thousands of patients, and costs more than $1 billion. Companies can't afford many studies like that and patients can't afford to wait years for potentially life-saving new medicines, said Don Berry, a biostatistician at the University of Texas MD Anderson Cancer Center.

He helped design the novel analytical method used in a study discussed Friday at the San Antonio Breast Cancer Symposium, an international conference on the disease.

Researchers testing a drug usually don't see results until they're all in, to prevent biasing the study. But several years ago, an unusual partnership decided to try a new way. It involves the National Cancer Institute, the Food and Drug Administration, drug companies, dozens of cancer research centers and charitable foundations.

The study, called I-SPY 2, enrolls small groups of women on experimental drugs or combinations, then gives them surgery to see what effect treatment had. The best result is a complete response, where no signs of cancer remain. Each patient's results are analyzed as they come in, and advanced statistical methods are used to calculate probabilities that the drug would help in various situations, depending on which women had a complete response.

"This allows us to learn and adapt from each patient as the study goes on," and results on early participants guide treatment that later participants get, said Dr. Hope Rugo of the University of California, San Francisco. When enough evidence indicates a high probability of success, the drug "graduates" to final-phase testing aimed at winning FDA approval.

On Friday, Rugo gave results on the first of seven drugs being tested - veliparib, made by AbbVie Inc., a North Chicago, Ill., company recently spun off from Abbott Laboratories. It is in a new class of experimental medicines called PARP inhibitors, which target an enzyme cancer relies on to grow.

The I-SPY 2 testing suggests that adding the chemotherapy drug carboplatin and veliparib to usual chemo before surgery improved outcomes for women with "triple negative" breast cancer - tumors that are not fueled by estrogen, progesterone or the gene that the medicine Herceptin targets.

Up to 20 percent of breast cancers are this type, and they're more common in young women, blacks and Hispanics, and women with certain breast cancer gene mutations.

Researchers were able to determine this after tests in only 71 women. They calculate that tests of only 300 women with triple negative tumors are needed to give a definitive answer, and that the drug has at least a 90 percent probability of success in such patients. If more types of cancer are included, the probability of success drops to 55 percent.

The results show that "we can get early reads on something that is worth pursuing" and bail quickly on treatments that don't help, said Dr. Carlos Arteaga of the Vanderbilt-Ingram Comprehensive Cancer Center in Nashville.

Last week, another company participating in the study, Puma Biotechnology Inc., said its experimental drug neratinib also had "graduated" and would enter a definitive study. Results of the early testing will be presented at a cancer conference next year.

The San Antonio meeting is sponsored by the American Association for Cancer Research, Baylor College of Medicine and the UT Health Science Center.
© Copyright 2015 AccessWDUN.com
All rights reserved. This material may not be published, broadcast, rewritten, or redistributed without permission.
S&P 500 index has its best year since 1997
The stock market closed out a record year with more all-time highs on Tuesday, giving U.S. indexes their biggest annual gains in almost two decades.
6:56PM ( 1 year ago )
Colorado readies for 'Green Wednesday' pot sales
Police were adding extra patrols around pot shops in eight Colorado towns that plan to allow recreational sales to anyone over 21 on Jan. 1.
1:52PM ( 1 year ago )
Kerry seeks framework for Mideast peace talks
A senior State Department official says Secretary of State John Kerry will try this week to get Israel and the Palestinians to agree on a framework for negotiating a final peace agreement, yet cautions against raising expectations for Kerry's latest round of shuttle diplomacy.
1:35PM ( 1 year ago )
U.S. News
Ethics laws set to take effect Jan. 1 in Georgia
After dominating much of the legislative session, a set of major ethics reforms is scheduled to take effect Jan. 1.
7:04PM ( 1 year ago )
Sex offender held in Hall County for failing to register
A 47-year-old man was booked into the Hall County Jail Tuesday, being held without bond for allegedly failing to register as a sex offender, his second such arrest.
6:09PM ( 1 year ago )
Pharmacy robberies may involve same suspect
Oakwood Police Tuesday afternoon released details in a pharmacy robbery they're investigating, similar to one that happened in the Hall County Tuesday morning.
5:46PM ( 1 year ago )
Local/State News
Hawaii's Big Island under tropical storm watch as Ignacio is upgraded to Category 4 hurricane
HONOLULU (AP) — The Big Island of Hawaii is bracing for high winds, heavy rain and ocean swells of up to 20 feet as strengthening Hurricane Ignacio approaches the state.Ignacio has grown to a Category...
8:20PM ( 9 hours ago )
At events both somber and raucous, Gulf Coast marks 10th Katrina anniversary, looks to future
NEW ORLEANS (AP) — As the church bells rang marking the decade since Hurricane Katrina struck the Gulf Coast, the 80-year-old woman wept softly into a tissue as she leaned against her rusting Oldsmobi...
6:38PM ( 11 hours ago )
US immigration patterns shift: India, China outpacing Mexico as more skilled workers arrive
DALLAS (AP) — Siddharth Jaganath wanted to return to India after earning his master's degree at Texas' Southern Methodist University. Instead, he built a new life in the U.S. over a decade, becoming a...
6:03PM ( 11 hours ago )
Fed Vice Chair Fischer leaves door open for a Sept. rate hike, saying inflation likely to rise
WASHINGTON (AP) — Federal Reserve Vice Chairman Stanley Fischer left the door open Saturday for a Fed rate increase in September, saying the factors that have kept inflation below the central bank's t...
4:31PM ( 13 hours ago )
Experts: GOP candidates' tough talk doesn't always square with facts of US-China relationship
CHARLESTON, S.C. (AP) — If there was ever a week for the Republican presidential candidates to talk tough on China, this was it: Spurred by the stock market's wild ride, they lashed out at the world's most populous nation.
9:34PM ( 1 day ago )